A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Identifieur interne : 000736 ( PubMed/Curation ); précédent : 000735; suivant : 000737A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Auteurs : Keith S. Reisinger [États-Unis] ; Sandra J. Holmes ; Paola Pedotti ; Ashwani Kumar Arora ; Maria LattanziSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2014.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (effets indésirables), Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Femelle, Grippe humaine (), Grippe humaine (virologie), Humains, Jeune adulte, Mâle, Polysorbates (administration et posologie), Polysorbates (effets indésirables), Sous-type H1N1 du virus de la grippe A (immunologie), Squalène (administration et posologie), Squalène (effets indésirables), Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Volontaires sains.
- MESH :
- administration et posologie : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins antigrippaux.
- effets indésirables : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Volontaires sains.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (adverse effects), Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral (blood), Female, Healthy Volunteers, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Middle Aged, Polysorbates (administration & dosage), Polysorbates (adverse effects), Squalene (administration & dosage), Squalene (adverse effects), Young Adult.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- chemical , adverse effects : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- chemical , blood : Antibodies, Viral.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Healthy Volunteers, Hemagglutination Inhibition Tests, Humans, Male, Middle Aged, Young Adult.
Abstract
During development of an A/H1N1 pandemic influenza vaccine, this study was performed to identify the antigen and adjuvant content which would provide optimal antibody response and persistence in adults and the elderly. Dose-sparing strategies, such as inclusion of adjuvants, are critical in ensuring the widest possible population coverage in the event of an influenza pandemic, despite a limited global capacity for vaccine manufacture.
DOI: 10.4161/hv.29393
PubMed: 25424947
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000736
Links to Exploration step
pubmed:25424947Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.</title><author><name sortKey="Reisinger, Keith S" sort="Reisinger, Keith S" uniqKey="Reisinger K" first="Keith S" last="Reisinger">Keith S. Reisinger</name><affiliation wicri:level="2"><nlm:affiliation>a Primary Physicians Research, Medicine; Pittsburgh, PA USA.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>a Primary Physicians Research, Medicine; Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Holmes, Sandra J" sort="Holmes, Sandra J" uniqKey="Holmes S" first="Sandra J" last="Holmes">Sandra J. Holmes</name></author><author><name sortKey="Pedotti, Paola" sort="Pedotti, Paola" uniqKey="Pedotti P" first="Paola" last="Pedotti">Paola Pedotti</name></author><author><name sortKey="Arora, Ashwani Kumar" sort="Arora, Ashwani Kumar" uniqKey="Arora A" first="Ashwani Kumar" last="Arora">Ashwani Kumar Arora</name></author><author><name sortKey="Lattanzi, Maria" sort="Lattanzi, Maria" uniqKey="Lattanzi M" first="Maria" last="Lattanzi">Maria Lattanzi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25424947</idno><idno type="pmid">25424947</idno><idno type="doi">10.4161/hv.29393</idno><idno type="wicri:Area/PubMed/Corpus">000736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000736</idno><idno type="wicri:Area/PubMed/Curation">000736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000736</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.</title><author><name sortKey="Reisinger, Keith S" sort="Reisinger, Keith S" uniqKey="Reisinger K" first="Keith S" last="Reisinger">Keith S. Reisinger</name><affiliation wicri:level="2"><nlm:affiliation>a Primary Physicians Research, Medicine; Pittsburgh, PA USA.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>a Primary Physicians Research, Medicine; Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Holmes, Sandra J" sort="Holmes, Sandra J" uniqKey="Holmes S" first="Sandra J" last="Holmes">Sandra J. Holmes</name></author><author><name sortKey="Pedotti, Paola" sort="Pedotti, Paola" uniqKey="Pedotti P" first="Paola" last="Pedotti">Paola Pedotti</name></author><author><name sortKey="Arora, Ashwani Kumar" sort="Arora, Ashwani Kumar" uniqKey="Arora A" first="Ashwani Kumar" last="Arora">Ashwani Kumar Arora</name></author><author><name sortKey="Lattanzi, Maria" sort="Lattanzi, Maria" uniqKey="Lattanzi M" first="Maria" last="Lattanzi">Maria Lattanzi</name></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adjuvants, Immunologic (adverse effects)</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Healthy Volunteers</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Middle Aged</term><term>Polysorbates (administration & dosage)</term><term>Polysorbates (adverse effects)</term><term>Squalene (administration & dosage)</term><term>Squalene (adverse effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Adjuvants immunologiques (effets indésirables)</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (sang)</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Polysorbates (administration et posologie)</term><term>Polysorbates (effets indésirables)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Squalène (administration et posologie)</term><term>Squalène (effets indésirables)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>Volontaires sains</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Healthy Volunteers</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Volontaires sains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During development of an A/H1N1 pandemic influenza vaccine, this study was performed to identify the antigen and adjuvant content which would provide optimal antibody response and persistence in adults and the elderly. Dose-sparing strategies, such as inclusion of adjuvants, are critical in ensuring the widest possible population coverage in the event of an influenza pandemic, despite a limited global capacity for vaccine manufacture.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25424947</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.</ArticleTitle><Pagination><MedlinePgn>2395-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.29393</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During development of an A/H1N1 pandemic influenza vaccine, this study was performed to identify the antigen and adjuvant content which would provide optimal antibody response and persistence in adults and the elderly. Dose-sparing strategies, such as inclusion of adjuvants, are critical in ensuring the widest possible population coverage in the event of an influenza pandemic, despite a limited global capacity for vaccine manufacture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Healthy subjects aged 18-64 years (n = 1240) and ≥65 years (n = 1352) were vaccinated with 1 of 8 investigational vaccine formulations varying in antigen quantity (3.75 µg to 30 µg of hemagglutinin) and MF59(®) adjuvant (none, half dose, or full dose). All subjects received 2 vaccine doses administered 3 weeks apart. Antibody response was assessed by hemagglutination inhibition assay 1 and 3 weeks after administration of first and second doses. Antibody persistence was assessed after 6 and 12 mo. Vaccine safety was monitored over 12 mo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All 8 investigational A/H1N1 vaccine formulations were well tolerated, and rapidly induced high antibody titers which met all of the Center for Biologics Evaluation and Research (CBER) and Committee for Medicinal Products for Human Use (CHMP) licensure criteria 3 weeks after one dose. The highest antibody titers were observed in participants vaccinated with higher quantities of antigen and adjuvant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A single vaccine dose containing 3.75 µg of A/California/7/2009 (H1N1) antigen with MF59 adjuvant was identified as optimal for young to middle-aged (18-64 years) and older (≥65 years) adult populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reisinger</LastName><ForeName>Keith S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>a Primary Physicians Research, Medicine; Pittsburgh, PA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Sandra J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Pedotti</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Ashwani Kumar</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Lattanzi</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSO100200700030C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H1N1</Keyword><Keyword MajorTopicYN="N">MF59</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25424947</ArticleId><ArticleId IdType="doi">10.4161/hv.29393</ArticleId><ArticleId IdType="pmc">PMC4896790</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2012 Aug;8(8):1119-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22854661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 24;27(31):4099-103</Citation><ArticleIdList><ArticleId IdType="pubmed">19410623</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 May 14;30(23):3470-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22446638</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Oct 13;365(15):1406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21995388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2010 Mar 5;85(10):81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20210260</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19237568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Mar 1;205(5):733-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22315336</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2010 Oct;126(4):e762-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20819892</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2010 Apr;10(4):639-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20218923</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2011 May;18(5):835-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21450978</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Sep 15;51(6):668-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19416838</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17544181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2011 Mar 4;86(10):86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21395187</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):243-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19453401</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Nov 16;27(49):6959-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19751689</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009;4(2):e4384</Citation><ArticleIdList><ArticleId IdType="pubmed">19197383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2012 Jul;31(7):e92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22481427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Jun 1;3(85):85ra48</Citation><ArticleIdList><ArticleId IdType="pubmed">21632986</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jul 6;30(32):4820-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22626675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin. 2011 May;7(5):539-48</Citation><ArticleIdList><ArticleId IdType="pubmed">21422814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2004 Aug;4(8):499-509</Citation><ArticleIdList><ArticleId IdType="pubmed">15288823</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jul 13;30(33):5030-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22472791</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2012 Apr;31(4):e59-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22418661</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jun 19;26(26):3209-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18462843</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2011 Dec;43(11-12):993</Citation><ArticleIdList><ArticleId IdType="pubmed">21851329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Mar 1;197(5):667-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18260764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin. 2011 Jan 1;7(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">21285531</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2011 Sep;43(9):702-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21534891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontology. 2003 May-Jun;49(3):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12679609</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jan 8;289(2):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12517228</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(9):e24384</Citation><ArticleIdList><ArticleId IdType="pubmed">21915319</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 May 6;362(18):1708-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20445182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2012 Jan;8(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22252007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000736 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000736 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25424947
|texte= A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25424947" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |